View news and innovations from PACK EXPO 2024
View all the latest news and innovations from PACK EXPO International 2024

GlaxoSmithKline to open new vaccine plant in France

To meet the growing demand for pediatric and adult vaccines, GSK is investing more than 500 million euros in a vaccine manufacturing plant to increase production in formulation, filling, freeze-drying, and packaging.

The facility, located in St. Amand-Les Eaux, will contribute to the production of a Cervarix, a candidate vaccine for the prevention of cervical cancer. The company is waiting for results of a Phase III clinical trial before it files Cervarix in the U.S. market.

GSK's new meningitis vaccines will also be manufactured at this site as well as a new flu vaccine to protect against seasonal influenza and a pediatric vaccine to protect against streptococcus pneumonia.

The new site will house a freeze-drying plant, which will transform vaccines from a liquid to a solid powder. This operation is used to enhance the shelf life and stability of a number of GSK's vaccines. The site will also be equipped with a liquid plant for filling syringes and vials, a packing plant and warehouse, a power plant, and quality control laboratories. The facility is expected to open in 2011.